mRNA Silencing Therapies Revolutionize hATTR Amyloidosis Treatment
In the treatment of hereditary transthyretin amyloidosis (hATTR amyloidosis), TTR mRNA silencing therapies, patisiran (Onpattro) and inotersen (Tegsedi), have become established as groundbreaking treatments effectively inhibiting disease progression. These agents fundamentally suppress the production of aberrant TTR protein, which causes the disease, and clinical trials have demonstrated their ability to halt the progression of polyneuropathy and even lead to symptom improvement in some patients.
Mechanism of Action and Clinical Data for Patisiran and Inotersen
Patisiran is an siRNA (small interfering RNA) encapsulated in lipid nanoparticles (LNPs), which specifically degrades TTR mRNA in the liver, thereby suppressing the production of abnormal TTR protein. The APOLLO trial demonstrated that patisiran halted the progression of polyneuropathy associated with hATTR amyloidosis, showing significant improvement compared to the placebo group.
Inotersen, on the other hand, is an ASO (antisense oligonucleotide) that binds to TTR mRNA and inhibits its translation, also suppressing the production of abnormal TTR protein. The NEURO-TTR trial showed that inotersen delayed the progression of neuropathy and improved quality of life. Both drugs have not only halted the progression of polyneuropathy but also led to improvements in neurological function in some patients, holding the potential to significantly alter the prognosis for hATTR amyloidosis patients.
Introduction of Next-Generation siRNA, Vutrisiran
Furthermore, within the realm of RNAi therapeutics, the next-generation siRNA, vutrisiran (Amvuttra), has already received FDA approval. Vutrisiran, similar to patisiran, targets TTR mRNA but, with enhanced chemical modifications and an improved LNP delivery system, allows for more convenient subcutaneous administration every three months. This represents a significant advancement in reducing patient burden and improving treatment adherence.
Background and Medical Impact
hATTR amyloidosis is a rare, progressive neurodegenerative disorder caused by the misfolding of TTR protein and amyloid fibril deposition in organs, affecting the heart, nerves, and digestive system, among others. Previous treatment options were limited, and it was often challenging to completely stop disease progression. The emergence of TTR mRNA silencing therapies like patisiran, inotersen, and vutrisiran has fundamentally transformed the hATTR amyloidosis treatment paradigm, significantly contributing to improved patient quality of life and survival. These drugs serve as excellent examples of the potent efficacy of RNA therapeutics against rare genetic diseases.
Future Outlook
The success of these mRNA silencing therapies marks a major milestone in RNA-based drug development, paving the way for similar technologies to be applied to other genetic diseases and conditions with high unmet medical needs. Particularly, advances in LNP technology are expected to further improve the safety, efficacy, and convenience of RNA therapeutics, enabling their broader application. The widespread adoption of these treatments for hATTR amyloidosis and the continued development of further improved drugs are anticipated to bring hope for the future of patients.
Source: https://oneamyloidosisvoice.com/news-meeting/patisiran-and-inotersen-hattr-amyloidosis
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments